×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| SUN PHARMACEUTICAL INDUSTRIES | 57056.5 | 7535.3 | 56019.6 | 3.1 | 3,82,358 | 33.4 |
| DIVIS LABORATORIES LTD. | 24760.0 | 5570.0 | 23570.0 | 20.95 | 159520 | 69.2 |
| CIPLA LTD. | 53172.4 | 13031.3 | 50461.7 | 16.12 | 125477 | 23.3 |
Sun Pharmaceutical Industries Ltd., with Security Code 524715, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 5,948.2 | 4,466.1 | 5,096.2 | 5,073.8 | 5,639.1 | 4,498.1 | 5,127.7 | 6,191.8 | 7,185.7 | 5,602.0 |
| Expenses | 3,587.6 | 3,517.3 | 3,709.9 | 3,714.8 | 3,745.6 | 3,737.0 | 3,789.1 | 4,488.3 | 4,196.2 | 3,710.8 |
| Operating Profit | 2,360.7 | 948.8 | 1,386.3 | 1,359.0 | 1,893.5 | 761.1 | 1,338.6 | 1,703.5 | 2,989.5 | 1,891.2 |
| OPM % | 39.69% | 21.24% | 27.2% | 26.78% | 33.58% | 16.92% | 26.11% | 27.51% | 41.6% | 33.76% |
| Other Income | -2,817.5 | 14.3 | 106.5 | 7.0 | 118.9 | 82.7 | 86.3 | 68.4 | 132.0 | -184.0 |
| Interest | 161.5 | 157.9 | 193.6 | 214.9 | 217.6 | 216.1 | 243.8 | 216.0 | 217.4 | 223.3 |
| Depreciation | 412.0 | 415.3 | 392.7 | 399.6 | 393.0 | 369.8 | 285.5 | 291.0 | 292.0 | 299.0 |
| Profit before tax | 1,907.5 | 539.1 | 906.5 | 821.3 | 1,401.8 | 257.9 | 895.6 | 1,264.9 | 2,612.1 | 1,472.5 |
| Tax % | -0.9% | -2.4% | -2% | -4% | -38.1% | -7.8% | -3.6% | -6.6% | -23.4% | 36.4% |
| Net Profit | -1,020.8 | 380.6 | 888.6 | 721.3 | 867.6 | 237.8 | 863.3 | 1,181.1 | 2,000.5 | 753.5 |
| EPS in Rs | -4.3 | 1.6 | 3.7 | 3 | 3.6 | 1 | 3.6 | 4.9 | 0 | 3.1 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 11,241.0 | 10,930.7 | 11,940.8 | 12,192.4 | 12,380.7 | 11,982.9 | 12,652.8 | 13,291.4 | 13,675.5 | 12,958.8 |
| Expenses | 8,244.5 | 8,162.4 | 8,616.5 | 9,028.7 | 8,911.4 | 8,955.6 | 9,055.9 | 9,352.4 | 9,671.0 | 9,249.4 |
| Operating Profit | 2,996.4 | 2,768.3 | 3,324.4 | 3,163.7 | 3,469.3 | 3,027.3 | 3,596.9 | 3,939.0 | 4,004.5 | 3,709.5 |
| OPM % | 26.66% | 25.33% | 27.84% | 25.95% | 28.02% | 25.26% | 28.43% | 29.64% | 29.28% | 28.62% |
| Other Income | 173.9 | 201.8 | -118.4 | 293.6 | 180.4 | 504.3 | 532.6 | 354.0 | 149.5 | 251.2 |
| Interest | 46.2 | 92.7 | 80.9 | 49.3 | 34.7 | 73.6 | 61.5 | 69.2 | 51.5 | 49.1 |
| Depreciation | 660.0 | 671.5 | 651.3 | 632.8 | 622.1 | 650.4 | 655.1 | 625.9 | 630.6 | 663.8 |
| Profit before tax | 2,464.2 | 2,377.3 | 2,796.6 | 2,775.2 | 3,062.7 | 2,909.3 | 3,412.8 | 3,597.9 | 3,788.0 | 3,609.4 |
| Tax % | -11.5% | -10% | -18.9% | -14% | -14.4% | -5.3% | -16.1% | -15.8% | -16.1% | -33.6% |
| Net Profit | 2,180.8 | 1,982.9 | 2,005.7 | 2,385.1 | 2,560.5 | 2,658.7 | 2,860.5 | 3,037.3 | 2,913.0 | 2,153.9 |
| EPS in Rs | 9 | 8.3 | 8.4 | 9.9 | 10.5 | 11.1 | 11.8 | 12.7 | 12.1 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 13% |
| 3 Years: | 14% |
| TTM: | 13% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 7% |
| 3 Years: | 73% |
| TTM: | 40% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 30% |
| 3 Years: | 24% |
| 1 Year: | 15% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 10% |
| 3 Years: | 11% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 24% |
| 3 Years: | 20% |
| TTM: | 15% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 30% |
| 3 Years: | 24% |
| 1 Year: | 15% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|